10X Genomics, Inc. Stock Price, News & Analysis

10x Genomics reported Q4 2022 revenue of $156.2 million, up 9% year-over-year, and FY 2022 revenue of $516.4 million, reflecting 5% growth compared to 2021. The increase was driven by strong sales of Chromium X Series instruments, despite a decline in China. New product launches, including the Xenium platform, were highlighted. However, gross margins fell to 76% in Q4 from 81% a year prior, with operating losses widening to $23.1 million. Net loss for Q4 was $17.2 million, slightly improved from $18.4 million in Q4 2021. For 2023, the company forecasts revenue between $580 million and $600 million.

10x Genomics (TXG) announced significant advancements at the 2023 AGBT General Meeting, showcasing its innovative platforms for single-cell analysis and spatial biology.

• Highlighting the scalability of the Chromium Flex platform, demonstrating its capability with data from an 8 million cell experiment.
• New capabilities for Visium CytAssist promise enhanced spatial discovery and a product pipeline including Visium HD.
• The Xenium platform now features a broader menu of customizable panels and the launch of the Xenium Catalyst Program to facilitate researcher access to high-quality data.

These developments reinforce 10x Genomics' leadership in biotechnology.

10x Genomics (TXG) plans to release its financial results for Q4 and full year 2022 on February 15, 2023, after market close. Management will host a conference call at 1:30 PM PT to discuss the results and provide insights on business developments and future outlook. The company's integrated solutions are essential in advancing biological research, with products utilized by top research institutions and pharmaceutical companies. The live webcast will be accessible on their website, with a replay available for at least 45 days.

10x Genomics, Inc. (Nasdaq: TXG), a leader in life sciences, will participate in the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California. Management is set to present on January 9 at 7:30 a.m. PT and participate in a panel on January 10 at 5:15 p.m. PT. The events can be accessed via a live and archived webcast on the company's Investors page. 10x Genomics specializes in products that analyze biological systems, with over 4,100 research citations and a robust patent portfolio.

10x Genomics (Nasdaq: TXG) has announced the commercial launch of the Xenium platform, enabling high-throughput in situ analysis of gene and protein expression at the subcellular level. The platform, which includes a versatile instrument and interactive software, allows researchers to explore complex biological data with high sensitivity. Key features include class-leading speed, broad gene panel compatibility, and intact tissue morphology compatibility. This launch signifies a notable advancement in biological analysis technology, aimed at answering critical research questions in fields like oncology and neurobiology.

10x Genomics (TXG) announced the commercial launch of BEAM (Barcode Enabled Antigen Mapping), a new solution aimed at accelerating antibody and T-cell receptor discovery. Built on the Chromium Single Cell Immune Profiling technology, BEAM allows comprehensive antigen screening, significantly improving therapeutic discovery timelines. The workflow is optimized for efficiency, taking only a week and promising robust data output. This marks the sixth major product launch from 10x Genomics in 2022, demonstrating the strength of its R&D pipeline, with shipping expected to begin in December 2022.

10x Genomics (Nasdaq: TXG) reported its third quarter 2022 financial results, revealing a revenue of $131.1 million, up 5% year-over-year and 14% quarter-over-quarter. The gross margin decreased to 77% from 80% due to increased costs and changes in product mix. Operating expenses surged 21% to $140.7 million, contributing to a significant operating loss of $40 million compared to $15.9 million last year. The net loss reached $41.9 million, widening from $17.2 million. 10x Genomics maintains its 2022 revenue guidance of $500 million to $520 million.

10x Genomics (Nasdaq: TXG) will host an Investor Day on December 8, 2022, at its headquarters in Pleasanton, CA, starting at 9:00 a.m. PT. The event will feature presentations from the leadership team and a Q&A session.

The live webcast will be accessible via the company's website, with an archive available for 45 days post-event. In-person attendance is limited and by invitation only. 10x Genomics specializes in life science technology, providing integrated solutions for biological analysis, with a strong presence in top research institutions worldwide.

10x Genomics (Nasdaq: TXG) will announce its third quarter 2022 financial results after market close on November 2, 2022. A conference call will be held at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results, business developments, and future outlook. Investors can access the live audio on the company's website, with playback available for at least 45 days post-event. 10x Genomics provides advanced life science technology solutions for analyzing biological systems, with strong adoption among leading global research institutions and pharmaceutical companies.